Stay updated on FLT3 Inhibitor Combo in AML Clinical Trial
Sign up to get notified when there's something new on the FLT3 Inhibitor Combo in AML Clinical Trial page.

Latest updates to the FLT3 Inhibitor Combo in AML Clinical Trial page
- Check2 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 in the page footer, with no impact on study data or navigation. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check24 days agoChange DetectedAdded Revision: v3.3.3 to the page history and removed HHS Vulnerability Disclosure and Revision: v3.3.2 from the footer.SummaryDifference0.1%

- Check53 days agoChange DetectedFooter now displays Revision: v3.3.2, and the previous Revision: v3.2.0 entry was removed.SummaryDifference0.0%

- Check60 days agoChange DetectedThe notice about government funding and operating status was removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check81 days agoChange DetectedNo substantive changes to the study record; the screenshots show only administrative version updates (e.g., status and contact/location entries). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check103 days agoChange DetectedSummary of changes: updated operating-status notice and a version bump to v3.2.0, replacing the previous v3.1.0.SummaryDifference7%

Stay in the know with updates to FLT3 Inhibitor Combo in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the FLT3 Inhibitor Combo in AML Clinical Trial page.